Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Boggio

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Current Opinion in Molecular Therapeutics|March 16, 2001
Cytokine gene-engineered vaccinesG Forni, K Boggio
European Cytokine Network|November 5, 1997
The dream of effective cytokine-based tumor vaccinesG Forni, K Boggio, M Giovarelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2001
Inhibition of mammary carcinogenesis by systemic interleukin 12 or p185neu DNA vaccination in Her-2/neu transgenic BALB/c miceE Di Carlo, S Rovero, K Boggio, et al.
Gene Therapy|April 21, 2001
Insertion of the DNA for the 163-171 peptide of IL1beta enables a DNA vaccine encoding p185(neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c miceS Rovero, K Boggio, E Di Carlo, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|October 26, 1999
Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular originE Di Carlo, M G Diodoro, K Boggio, et al.
Cancer Research|April 18, 2001
A light, nontoxic interleukin 12 protocol inhibits HER-2/neu mammary carcinogenesis in BALB/c transgenic mice with established hyperplasiaL Cifaldi, E Quaglino, E Di Carlo, et al.
Cancer Research|February 10, 2000
Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic miceK Boggio, E Di Carlo, S Rovero, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 25, 2000
DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c miceS Rovero, A Amici, E Di Carlo, et al.
The Journal of Experimental Medicine|August 4, 1998
Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic miceK Boggio, G Nicoletti, E Di Carlo, et al.
Vaccine|January 5, 2000
A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative thais.AFRIMS-RIHES Vaccine Evaluation Group. Armed Forces Research Institute of Medical Sciences and the Research Institute for Health SciencesS Nitayaphan, C Khamboonruang, N Sirisophana, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Current Opinion in Molecular Therapeutics|March 16, 2001
Cytokine gene-engineered vaccinesG Forni, K Boggio
European Cytokine Network|November 5, 1997
The dream of effective cytokine-based tumor vaccinesG Forni, K Boggio, M Giovarelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2001
Inhibition of mammary carcinogenesis by systemic interleukin 12 or p185neu DNA vaccination in Her-2/neu transgenic BALB/c miceE Di Carlo, S Rovero, K Boggio, et al.
Gene Therapy|April 21, 2001
Insertion of the DNA for the 163-171 peptide of IL1beta enables a DNA vaccine encoding p185(neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c miceS Rovero, K Boggio, E Di Carlo, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|October 26, 1999
Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular originE Di Carlo, M G Diodoro, K Boggio, et al.
Cancer Research|April 18, 2001
A light, nontoxic interleukin 12 protocol inhibits HER-2/neu mammary carcinogenesis in BALB/c transgenic mice with established hyperplasiaL Cifaldi, E Quaglino, E Di Carlo, et al.
Cancer Research|February 10, 2000
Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic miceK Boggio, E Di Carlo, S Rovero, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 25, 2000
DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c miceS Rovero, A Amici, E Di Carlo, et al.
The Journal of Experimental Medicine|August 4, 1998
Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic miceK Boggio, G Nicoletti, E Di Carlo, et al.
Vaccine|January 5, 2000
A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative thais.AFRIMS-RIHES Vaccine Evaluation Group. Armed Forces Research Institute of Medical Sciences and the Research Institute for Health SciencesS Nitayaphan, C Khamboonruang, N Sirisophana, et al.
Pageof 1